Snowdon Contact us

Home / Company

The company

Founded in 2007, built around a discovery platform and an academic founder.

About us

Snowdon, Inc.

Snowdon is a biopharmaceutical company specializing in the discovery and development of novel small-molecule therapeutics for the treatment of pain, infectious diseases and nervous system disorders.

By applying its proprietary E-Prospector platform technology together with its expertise in medicinal chemistry, pharmacology and computational drug design, Snowdon reduces the time, cost and risk of drug discovery.

The company is based at the Princeton Research Center in Monmouth Junction, New Jersey.

At a glance

History

Founded in 2007

Snowdon was founded in 2007 by William J. Welsh, PhD, the Norman H. Edelman Professor in the Department of Pharmacology at UMDNJ-Robert Wood Johnson Medical School. The company was established through an equity investment by Foundation Venture Capital Group LLC together with grants from the New Jersey Commission on Science & Technology and the National Institutes of Health.

  • 2007

    Founded

    Snowdon, Inc. is founded by William J. Welsh, PhD, the Norman H. Edelman Professor in the Department of Pharmacology at UMDNJ-Robert Wood Johnson Medical School, through an equity investment by Foundation Venture Capital Group together with grants from the New Jersey Commission on Science & Technology and the NIH.

  • 2007-2010

    A pipeline, and a contract

    The company builds out small-molecule programs in pain, tuberculosis, toxoplasmosis and Fragile X Syndrome, and in 2010 wins a three-year DTRA-TMT contract for work on biowarfare pathogens.

  • 2015

    A property dispute

    The Armed Services Board of Contract Appeals decides ASBCA No. 59705, involving equipment bought under the DTRA contract; the appeal is denied and the government awarded $47,500 plus interest.

Office corridor
The company’s facilities pages carried this image.

Management

Stephen D. Albano, CPA, served as interim CEO after eighteen months as the company’s financial consultant and controller; Dr. Richard D. Wood was Vice President of Research and Development.

Board of directors

Investors, clinicians and technology transfer

James M. Golubieski

Chair

President of the Foundation Venture Capital Group, LLC and the New Jersey Health Foundation; former CFO of Array Medical; previously COO of Glendale National Bank and ten years with KPMG.

Gary Grover, Ph.D.

Director

Professor of Physiology and Biophysics at Robert Wood Johnson Medical School; formerly of Bristol-Myers Squibb and Eurofins Scientific-PSL; author of 200 peer-reviewed manuscripts.

Robert B. Royds, M.D.

Director

Medical Director and Chairman of Theradex, Princeton NJ; over 30 years in clinical research and development; Principal Investigator for the Clinical Trials Monitoring Service for the National Cancer Institute since 1982.

Vincent Smeraglia, Esq.

Observer

Director of the UMDNJ Office of Patents & Licensing, overseeing technology transfer and commercialisation of university intellectual property.

Working with Snowdon

Partnering, licensing and scientific enquiries

The company published one inbox for enquiries and one for employment. Both are reproduced as they stood.

Contact us